Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1

Interventions

Cytarabine 26Daunorubicin 10Mitoxantrone 8Idarubicin 8fludarabine phosphate 6Etoposide 6Busulfan 6Methotrexate 5Gemtuzumab 5Filgrastim 5Clofarabine 5tipifarnib 4alvocidib 4Vorinostat 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Decitabine 4Antilymphocyte Serum 4sargramostim 3Observation 3Mycophenolic Acid 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporine 3Cyclophosphamide 3CPX-351 3Bortezomib 3Azacitidine 3Whole-Body Irradiation 2Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Monocytic, Acute × Antineoplastic Agents × Clear all
NCT00831766 2020-12-22

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
51 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡